000140609 001__ 140609
000140609 005__ 20240613145427.0
000140609 0247_ $$2doi$$a10.1016/j.cca.2019.02.005
000140609 0247_ $$2pmid$$apmid:30735665
000140609 0247_ $$2ISSN$$a0009-8981
000140609 0247_ $$2ISSN$$a1873-3492
000140609 0247_ $$2altmetric$$aaltmetric:55558080
000140609 037__ $$aDZNE-2020-06931
000140609 041__ $$aEnglish
000140609 082__ $$a610
000140609 1001_ $$0P:(DE-HGF)0$$aBouter, Caroline$$b0$$eCorresponding author
000140609 245__ $$aComparison between amyloid-PET and CSF amyloid-β biomarkers in a clinical cohort with memory deficits.
000140609 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2019
000140609 264_1 $$2Crossref$$3print$$bElsevier BV$$c2019-05-01
000140609 3367_ $$2DRIVER$$aarticle
000140609 3367_ $$2DataCite$$aOutput Types/Journal article
000140609 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1718283209_11704
000140609 3367_ $$2BibTeX$$aARTICLE
000140609 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000140609 3367_ $$00$$2EndNote$$aJournal Article
000140609 520__ $$aWith increasing prevalence of Alzheimer's disease (AD) and advances in research of therapeutic approaches, an early and accurate in-vivo diagnosis is crucial. Different biomarkers that are able to identify AD are currently in focus. However, whether and to which extend results of cerebrospinal fluid (CSF) and imaging biomarkers are comparable, is unclear. This study aims to correlate CSF and amyloid imaging biomarkers comparing them to cognitive measurements in order to determine whether these methods provide identical or complementary information. The study comprises 33 consecutive patients with suspected cognitive decline that underwent lumbar puncture for CSF biomarker analysis and Amyloid-PET/CT within the diagnostic evaluation of memory impairment. Amyloid PET/CTs were evaluated visually and quantitatively. CSF and imaging data were retrospectively evaluated and results were compared to cognition tests, age, gender, and ApoE status. Global cortex SUVr levels correlated highly with CSF Aβ42/40 and moderately with Aβ42 but not with Aβ40. Global cortex SUVr and Aβ42/40 correlated with mini mental status examination. This study indicates that Amyloid-PET and CSF biomarkers might not reflect identical clinical information and a combination of both seems to be the most accurate way to characterize clinically unclear cognitive decline.
000140609 536__ $$0G:(DE-HGF)POF3-342$$a342 - Disease Mechanisms and Model Systems (POF3-342)$$cPOF3-342$$fPOF III$$x0
000140609 542__ $$2Crossref$$i2019-05-01$$uhttps://www.elsevier.com/tdm/userlicense/1.0/
000140609 588__ $$aDataset connected to CrossRef, PubMed,
000140609 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000140609 650_7 $$2NLM Chemicals$$aApolipoproteins E
000140609 650_7 $$2NLM Chemicals$$aBiomarkers
000140609 650_2 $$2MeSH$$aAged
000140609 650_2 $$2MeSH$$aAging: metabolism
000140609 650_2 $$2MeSH$$aAmyloid beta-Peptides: cerebrospinal fluid
000140609 650_2 $$2MeSH$$aApolipoproteins E: cerebrospinal fluid
000140609 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000140609 650_2 $$2MeSH$$aCase-Control Studies
000140609 650_2 $$2MeSH$$aCognition
000140609 650_2 $$2MeSH$$aCohort Studies
000140609 650_2 $$2MeSH$$aFemale
000140609 650_2 $$2MeSH$$aHumans
000140609 650_2 $$2MeSH$$aMale
000140609 650_2 $$2MeSH$$aMemory Disorders: cerebrospinal fluid
000140609 650_2 $$2MeSH$$aMemory Disorders: diagnostic imaging
000140609 650_2 $$2MeSH$$aMemory Disorders: physiopathology
000140609 650_2 $$2MeSH$$aMiddle Aged
000140609 650_2 $$2MeSH$$aPositron Emission Tomography Computed Tomography
000140609 650_2 $$2MeSH$$aRetrospective Studies
000140609 650_2 $$2MeSH$$aSex Characteristics
000140609 7001_ $$0P:(DE-HGF)0$$aVogelgsang, Jonathan$$b1
000140609 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b2$$eLast author$$udzne
000140609 77318 $$2Crossref$$3journal-article$$a10.1016/j.cca.2019.02.005$$b : Elsevier BV, 2019-05-01$$p62-68$$tClinica Chimica Acta$$v492$$x0009-8981$$y2019
000140609 773__ $$0PERI:(DE-600)1499920-1$$a10.1016/j.cca.2019.02.005$$gVol. 492, p. 62 - 68$$p62-68$$q492<62 - 68$$tClinica chimica acta$$v492$$x0009-8981$$y2019
000140609 8564_ $$uhttps://pub.dzne.de/record/140609/files/DZNE-2020-06931_Restricted.pdf
000140609 8564_ $$uhttps://pub.dzne.de/record/140609/files/DZNE-2020-06931_Restricted.pdf?subformat=pdfa$$xpdfa
000140609 909CO $$ooai:pub.dzne.de:140609$$pVDB
000140609 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811317$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000140609 9131_ $$0G:(DE-HGF)POF3-342$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vDisease Mechanisms and Model Systems$$x0
000140609 9141_ $$y2019
000140609 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-17$$wger
000140609 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN CHIM ACTA : 2021$$d2022-11-17
000140609 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-17
000140609 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-17
000140609 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-17
000140609 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-17
000140609 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-17
000140609 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-17
000140609 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-17
000140609 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-17
000140609 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCLIN CHIM ACTA : 2021$$d2022-11-17
000140609 9201_ $$0I:(DE-2719)1410006$$kAG Wiltfang$$lMolecular biomarkers for predictive diagnostics of neurodegenerative diseases$$x0
000140609 980__ $$ajournal
000140609 980__ $$aVDB
000140609 980__ $$aI:(DE-2719)1410006
000140609 980__ $$aUNRESTRICTED